Patent: 9,512,115
✉ Email this page to a colleague
Summary for Patent: 9,512,115
| Title: | Inhibitors |
| Abstract: | The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water. ##STR00001## |
| Inventor(s): | Heiser; Ulrich (Halle/Saale, DE), Buchholz; Mirko (Halle/Saale, DE), Sommer; Robert (Magdeburg, DE), Meyer; Antje (Halle/Saale, DE), Demuth; Hans-Ulrich (Halle/Saale, DE) |
| Assignee: | PROBIODRUG AG (Halle (Saale), DE) |
| Application Number: | 14/775,785 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,512,115
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Jubilant Hollisterstier Llc | N/A | positive skin test control-histamine | Injection | 103891 | 03/13/1924 | ⤷ Try a Trial | 2039-02-26 |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2039-02-26 |
| Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2039-02-26 |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2039-02-26 |
| Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 11/23/2004 | ⤷ Try a Trial | 2039-02-26 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
